GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (STU:2B30) » Definitions » Total Long-Term Liabilities

Xeris Biopharma Holdings (STU:2B30) Total Long-Term Liabilities : €236.3 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Xeris Biopharma Holdings Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Xeris Biopharma Holdings's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €236.3 Mil.

Xeris Biopharma Holdings Total Long-Term Liabilities Historical Data

The historical data trend for Xeris Biopharma Holdings's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Total Long-Term Liabilities Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 79.89 115.13 213.07 214.75 240.88

Xeris Biopharma Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 250.89 255.97 232.83 240.88 236.35

Xeris Biopharma Holdings Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Xeris Biopharma Holdings Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (STU:2B30) » Definitions » Total Long-Term Liabilities
Comparable Companies
NAGE PRAX GYRE NUVB LENZ ZYME ELVN NRIX IMNM QURE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
XERS:USA 0A8E:UK
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Website
https://www.xerispharma.com
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines